Skip to content

Comparison of butorphanol with conventional analgesia on postoperative pain and Th17/Treg levels after laparoscopic colorectal cancer surgery: a randomized controlled trial

Application of Butorphanol Analgesia in Colorectal Cancer Surgery and Its Effects on Th17 and Treg Cells

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116805
Enrollment
Unknown
Registered
2026-01-15
Start date
2022-07-20
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Experimental Group: Butorphanol Group (B Group):Postoperative Analgesia Management:Intravenous injection of butorphanol 25 µg/kg (diluted to 10 mL, administered over 5 minutes) before peritoneal closu
Control Group: Sufentanil Group (S Group):Postoperative Analgesia:Intravenous injection of sufentanil 0.2 µg/kg (diluted to 10 mL, administered over 5 minutes) before peritoneal closure.Postoperative

Sponsors

Sanya Central Hospital (Hainan Third People's Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for colorectal cancer in the Chinese Guidelines for Diagnosis and Treatment of Colorectal Cancer (2020 Edition) [12] and is staged according to the TNM staging criteria of the 7th edition of the American Joint Committee on Cancer [13]; 2. Has no tumor metastasis to surrounding or adjacent tissues and organs before surgery; 3. Age >= 18 years and <= 75 years, American Society of Anesthesiologists (ASA) grade I or I, that is, the organ system function is normal or fully compensated; 4. Has not used analgesics before surgery; 5. Patients voluntarily participate in this study.

Exclusion criteria

Exclusion criteria: 1. History of abdominal surgery; 2. Acute infection, autoimmune disease or chronic inflammatory disease; 3. Patients who have undergone palliative surgical resection; 4. History of allergy to anesthetic drugs or drug abuse; 5. Patients with liver or kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Postoperative 6-hour rest/cough VAS score;Postoperative 12-hour rest/cough VAS score;Postoperative 24-hour rest/cough VAS score;Postoperative 48-hour rest/cough VAS score;

Secondary

MeasureTime frame
Immunological Parameters: Peripheral blood Th17 cell levels;Immunological Parameters:Peripheral blood Treg cell levels ;Blood loss;Blood transfusion volume;Operative time;hospitalization duration;time to first flatus;incidence of nausea and vomiting;postoperative infection rate;

Countries

China

Contacts

Public ContactXu Xia

Sanya Central Hospital (Hainan Third People's Hospital)

xuxia1972@126.com+86 183 0897 4870

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026